This paper is aimed to explore the efficiency of a noval gene-target therapy system in hepatocellular carcinoma(HCC) treatment in vitro,by using survivin gene as the target.A new fusion promoter(AV) driving pcDNA3.1(-)AV plasmid,which contained the cytomegalovirus(CMV) enhancer and alpha-fetoprotein(AFP) promoter,was constructed by molecular biologic method.The eukaryotic expression plasmid pcDNA3.1(-)AVGFP and pcDNA3.1(-)AVsiRNA-survivin were constructed by cloning and inserting the green fluorescent prote...